Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Cell-free protein expression (CFPE) is used to produce recombinant proteins in solution without the involvement of living cells. This method is widely used in enzyme engineering, protein labelling, protein purification, protein-protein interaction, and high throughput mutant production. It is also used for analysing elements required for protein stability, degradation, and folding. The cell-free protein expression method is time efficient and convenient, which allows the incorporation of non-natural amino acids, and provides enhanced stability and specificity. The growth of the Asia-Pacific Cell Free Protein Expression market is driven by rise in prevalence of cancer and infectious diseases in Asian countries along with increasing R&D activities in proteomics and genomics. Furthermore, the rise in demand for personalized medicines for the treatment of chronic diseases is expected to positively contribute to the growth of the market.
The growth of the market is driven by the rising prevalence of chronic diseases such as cancer, diabetes, cardiovascular disease, and others. The International Diabetes Federation estimated that there were 382 million people with diabetes in 2013, a number surpassing its earlier predictions. More than 60% of the people with diabetes live in Asia, with almost one-half in China and India combined. According to the World Health Organization, 55% of all deaths in the Southeast Asia region are due to non-communicable diseases NCDs – that is nearly 8 million people every year. Thus, rising cases of chronic diseases such as cancer, diabetes, cardiovascular disease, and others create a demand for personalized medicine which can be achieved using cell-free protein expression. This is expected to drive the growth of the Asia-Pacific cell-free protein expression market over the forecast period. Furthermore, the rise in utilization of cell-free protein expression in the pharmaceutical industry for developing protein-based therapeutics, such as antibodies, antimicrobials, and cytokines, for treating cancer and infectious diseases is expected to positively impact the growth of the market.
Rising investments in R&D along with an increase in innovative research projects is expected to provide an ample opportunity for the market. For instance, researchers from Australian National University (ANU) have developed eCells (encapsulated cells) - a new protein production platform based on microbial cells, in which cell walls are replaced with permeable polymer encapsulations to gain full control over essential biochemical processes for cell-free protein synthesis.
The cell-free protein expression offers low protein production, making it unsuitable for large industrial applications. This, in turn, is likely to hamper the growth of the market. Additionally, the high cost and short reaction scale of cell-free protein expression are expected to restrain the growth of the market.
The cost of the research activities involved in cell-free protein expression is significantly high, it may impact the growth of the market in developing nations. Also, a lack of skilled labour in low-income nations is expected to be a major challenge for the market’s growth over the forecast period.
The report provides an in-depth analysis of the Asia-Pacific Cell Free Protein Expression market, market size, and compound annual growth rate (CAGR) for the forecast period of 2023-2029, considering 2022 as the base year. An increase in prevalence of chronic disease has led to a rise in demand for cell free protein expression techniques in various applications, and therefore, the market is expected to witness growth at a specific CAGR from 2023-2029.
The Asia-Pacific Cell Free Protein Expression market comprises of different market segments like product, application, end users and country.
By product, the Asia-Pacific Cell Free Protein Expression market includes the key segments like
E. coli cell-free protein expression system is expected to dominate the market over the forecast period. E. coli cell-free protein expression systems can synthesize a broad variety of proteins, including soluble proteins such as enzymes or reporters, proteins with disulphide bonds such as antibodies and membrane proteins such as channels or transporter.
The wheat germ cell-free protein expression system is expected to witness fastest growth over the estimated time period. This system offers optimal environment for protein synthesis by allocating all metabolic resources to the protein in question, as opposed to basic cellular mechanisms. It is a key factor driving the growth of the segment.
The Asia-Pacific Cell Free Protein Expression market finds key applications in
The enzyme engineering segment is expected to dominate the market over the forecast period. Over the years, cell free protein expression method has become an established tool for rapid protein synthesis in order to accelerate the discovery of new enzymes and the development of proteins with improved characteristics. This is a key factor driving the growth of the segment.
High throughput production is expected to witness high growth over the forecast period. The cell free protein expression method is widely used in high-throughput functional genomics and proteomics, with significant advantages compared to protein expression in live cells.
The Asia-Pacific Cell Free Protein Expression market has major end users like
The pharmaceutical and biotechnology companies are expected to lead the market over the estimated time period. The expansion of current manufacturing capacities for biopharmaceuticals is stimulating demand for cell-free protein expression products. For instance, in February 2022 Takara Bio Inc. announced the opening of an expansion of its manufacturing facility, the Center for Gene and Cell Processing in Shiga, Japan. The development of a GMP facility will meet the growing demand for contract development and manufacturing firms as well as the need for a wider range of raw materials and manufacturing techniques.
Furthermore, the academic and research institutes are expected to witness high growth over the forecast period due to the rise in investments in R&D activities in proteomics and genomics.
The Asia-Pacific Cell Free Protein Expression market is studied for the following countries
China is expected to dominate the market over the forecast period. The rise in prevalence of chronic diseases such as cancer, coupled with investments and funding in drug discovery research are key factors driving the growth of the market in the region. According to the National Center for Health Statistics, in 2022, there will be approximately 4,820,000 new cancer cases, and 3,210,000 cancer deaths in China. Thus, rise in prevalence of chronic diseases is expected to drive the growth of the market in China.
Japan is anticipated to witness an increasing demand for the cell free protein expression method owing to the strategic activities of key market players. For instance, In July 2021, CELLFREE SCIENCES CO., LTD, a Japanese business, received funding through the Ehime Prefecture's New Growth Manufacturing Company Comprehensive Support Program.
Axiom MRC provides a 360-degree analysis of micro and macro-economic factors on the Asia-Pacific Cell Free Protein Expression market. In addition, a complete analysis of changes in the Asia-Pacific Cell Free Protein Expression market expenditure, economic and international policies on the supply and demand side is provided in this exclusive report. The report also studies the impact of pandemic on Asia-Pacific economies, international trade, business investments, GDP, and the marketing strategies of key players present in the market.
The COVID-19 pandemic and the lockdown restrictions imposed by various governments all over the world have had a catastrophic impact on most industries around the world. The pandemic had a positive effect on the market. According to the article, "Harnessing proteomics could improve therapeutic approaches to COVID-19," published in November 2020, the development of therapeutic and preventive strategies requires an accurate understanding of proteins' role in the SARS-CoV-2 infection process and progression of COVID-19. The expression of cell-free proteins has been widely used for the development of various treatments, including COVID-19. This is expected to contribute to the growth of the market in the upcoming years.
The competitive landscape analysis of the Asia-Pacific Cell Free Protein Expression market is primarily focused on expanding the growth of the cell free protein expression industry in the Asia-Pacific region with new product innovation, business expansion, increasing presence of a range of manufacturers operating in the cell free protein expression sector has led to growing demand for the market. Besides, the market offers range of products in different applications to fulfil the required demand of consumer which is further contributing healthy growth in the market.
The key players studied in market are
September 2021: Sanofi had entered into a definitive merger agreement with Kadmon Holdings, Inc. a biopharmaceutical company that discovers, and develops therapies for disease areas with significant unmet medical needs. The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.
February 2020: Indian Institute of Science Education and Research (IISER) Bhopal Researchers had invented a new technology that can deliver active molecules to specific sections of proteins.
By product, the Asia-Pacific Cell Free Protein Expression market includes key segments like E. coli cell-free protein expression system, wheat germ cell-free protein expression system, rabbit reticulocytes cell-free protein expression system, insect cell cell-free protein expression system, human cell-free protein expression system and others. The E. coli cell-free protein expression system is expected to dominate the market over the forecast period. The Asia-Pacific Cell Free Protein Expression market finds key applications in enzyme engineering, high throughput production, protein labeling, protein-protein interaction, protein purification and others. The enzyme engineering segment is expected to lead the market over the forecast period. The Cell Free Protein Expression market has major end users like hospitals and clinics, pharmaceutical and biotechnology companies, academic and research institutes and others. The pharmaceutical and biotechnology companies’ are expected to dominate the market over the estimated time period. The Asia-Pacific Cell Free Protein Expression market is studied for countries like China, Japan, India, and Rest of Asia-Pacific. China is expected to dominate the market over the forecast period.
| Market
Sizing for Year: | 2019-2029 |
| Base
Year: | 2022 |
| Forecast
Period: | 2023-2029 |
| Value: | USD million |
| Market
Segment studied: | Product Application End Users |
| Market
Players and its Competitors: | Merck KGaA Cube Biotech GmbH CellFree Sciences Co., Ltd. Promega Corporation Thermo Fisher Scientific Creative Biolabs Bioneer Corporation Jena Bioscience GmbH New England Biolabs Biotechrabbit GmbH LenioBio GmbH Moderna Therapeutics GeneCopoeia, Inc Takara Bio Sutro Biopharma Inc |
